Clinical data and state rules are separate facts. Both are shown; neither is a decision.
Related to bremelanotide (Vyleesi), whose label documents transient blood-pressure rise and nausea; melanotan II is less selective. These effects can stack with psilocybin's BP rise and nausea. Grey-market "research" vials carry unknown content, dose and sterility.
No peptide in this section has published human data on interaction with psilocybin or any classic psychedelic. Entries rest on each agent's own pharmacology, and many have no human pharmacokinetic data at all. For unapproved products the larger practical concern is unknown content, dose and sterility. Regulatory status changes quickly (FDA compounding actions in 2026); check the date on each entry.
No pharmacology properties of concern are listed for this record.
No provision names this medication or its class.
Colorado · checked 2026-09-30No provision names this medication or its class.
Oregon · checked 2026-09-30New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-09-30No condition named in state rules is linked to this medication.